Osimertinib and its use in the treatment of non‑small cell lung carcinoma in the Czech Republic

06/2018

MUDr. Daniel Krejčí; MUDr. Jana Krejčí; doc. MUDr. Norbert Pauk, Ph.D.

Klinika pneumologie a hrudní chirurgie 3. LF UK a Nemocnice Na Bulovce, Praha

SUMMARY

It has been shown that patients with non-small cell lung cancer with confirmed mutation of epidermal growth factor receptors significantly benefit from treatment by tyrosine kinase inhibitors. However, resistant mutations develop within approximately 10 months, of which 60 % are formed by T790M mutations. Multiple clinical trials showed that osimertinib is an efficient molecule in both patients with common epidermal growth factor receptor mutations as well as in those with T790M positivity. AURA III met its primary endpoint showing that the PFS was significantly prolonged in T790M positive patients being treated with osimertinib compared to standard chemotherapy in the second line. Clinical study FLAURA also showed significant prolongation PFS in comparison to standard first line treatment in epidermal growth factor receptor mutated patients. Osimertinib has favorable safety profile and good efficacy even in CNS. In the Czech Republic osimertinib is registered for the first line treatment of patients with activating epidermal growth factor receptor mutations and for patients with confirmed T790M mutations. At the time that this article was written, full reimbursement of osimertinib is not available in the Czech Republic.

KEY WORDS

epidermal growth factor receptor, non-small cell lung cancer, Osimertinib